Evolving Pharmacology Of Depression: Beyond The Monoamine Hypothesis

Description

Virtual Forum: Evolving Pharmacology Of Depression: Beyond The Monoamine Hypothesis

Location: Online Via PsychU.org

Description: According to the World Health Organization, major depressive disorder (MDD) currently impacts 300 million individuals worldwide and is the leading cause of disability globally. Current treatment strategies for depression are effective in one-third to half of those seeking treatment, leaving a large unmet need for new therapeutic options. Since the 1960’s, traditional pharmacological treatment strategies have centered on modulating serotonin, dopamine, and/or norepinephrine neurotransmitters systems. However, within the last few decades, research has begun to explore other neurotransmitter systems like GABA, glutamate, and opioid neuropeptide, as well as targets within the neuroendocrine, genetic, and inflammatory signaling systems that are moving psychiatry beyond the monoamine hypothesis.

In this Virtual Forum, you will hear from Richard Jackson, MD, and Robin Nelson, MD, as they discuss some of the critical issues facing depression pathophysiology and treatment in current behavioral health care settings, focused on strategies moving beyond the traditional monoamine neurotransmitter targets and modalities with novel mechanisms of action that are on the horizon for depression treatment.

Speakers are paid consultants to Otsuka Pharmaceutical Development & Commercialization, Inc.

Event Speakers

Robin Nelson, MD
Featured Speaker

Robin Nelson, MD, currently serves as a Section Editor for PsychU. He is also a Psychiatrist at DGR Comprehensive Behavioral Health, LLC in Wyomissing, PA, and an attending psychiatrist at the Caron Foundation Treatment Center in Wernersville, PA.

Dr. Nelson received his MD from Duke University’s School of Medicine. He completed his residency in Duke University’s Psychiatric Residency Education Program. Dr. Nelson is board certified by the American Board of Psychiatry and Neurology.

Richard Jackson, MD
Featured Speaker

Richard Jackson, MD, is one of the founders and owners of the Neurobehavioral Medicine Group, an outpatient psychiatric treatment center in Bloomfield Hills, MI. He currently serves as an Associate Clinical Professor for the Department of Psychiatry at Wayne State University and at the William Beaumont School of Medicine at Oakland University; as an Assistant Adjunct Clinical Professor for the School of Medicine in the Department of Psychiatry at the University of Michigan; and as Director of the Forensic Psychiatry Rotation for the Psychiatric Residency Program at Henry Ford Hospital. Dr. Jackson is also a Senior Psychiatrist at the Women’s Huron Valley Correctional Facility in Ypsilanti, MI.

Dr. Jackson received his MD from Wayne State University School of Medicine.

 

Rachel Self, PhD
Moderator

Rachel Self, PhD, currently serves as a Senior Medical Science Liasion for Otsuka Pharmaceutical Development & Commercialization, Inc.